Sugi Predict

Sugi Predict / Targets / PSMA6

PSMA6

Proteasome subunit alpha type-6 · P60900 · PSMA6 on Sugi Atlas →

23,032 patent compounds predicted against PSMA6, 15,721 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL605949 SCHEMBL605949 0.54 15/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL609327 SCHEMBL609327 0.55 12/20
SCHEMBL607553 SCHEMBL607553 0.54 12/20
SCHEMBL606932 SCHEMBL606932 0.53 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL1477893 SCHEMBL1477893 0.53 12/20
SCHEMBL609081 SCHEMBL609081 0.52 12/20
SCHEMBL606926 SCHEMBL606926 0.52 12/20
SCHEMBL606344 SCHEMBL606344 0.51 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1327404 SCHEMBL1327404 0.50 12/20
SCHEMBL607035 SCHEMBL607035 0.61 11/20
SCHEMBL609733 SCHEMBL609733 0.60 11/20
SCHEMBL609324 SCHEMBL609324 0.60 11/20
SCHEMBL605158 SCHEMBL605158 0.59 11/20
SCHEMBL606315 SCHEMBL606315 0.59 11/20
SCHEMBL1477637 SCHEMBL1477637 0.57 11/20
SCHEMBL609290 SCHEMBL609290 0.57 11/20
SCHEMBL607972 SCHEMBL607972 0.55 11/20

Clinical trials — most relevant to PSMA6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy PHASE4RECRUITING
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function PHASE2ACTIVE_NOT_RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer PHASE2COMPLETED
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours: PHASE2ACTIVE_NOT_RECRUITING
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors PHASE1COMPLETED
Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer PHASE1COMPLETED
A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 PHASE1COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients nanNOT_YET_RECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer. nanSUSPENDED
The Effect of ADT on PSMA-PET. nanUNKNOWN
Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer nanRECRUITING
Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 nanCOMPLETED
PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell Carcinomas nanCOMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PSMA6 binder may also engage these)

ProteinNameSimilarity
Q9QUM9 — 1.000 Q9QUM9 →
Q2YDE4 — 1.000 Q2YDE4 →
P60901 — 0.998 P60901 →
O48551 — 0.997 O48551 →
P21243 — 0.996 P21243 →
O81146 — 0.995 O81146 →
Q9LSU3 — 0.994 Q9LSU3 →
Q9CWH6 — 0.994 Q9CWH6 →
Q9XZJ4 — 0.994 Q9XZJ4 →
Q0J006 — 0.993 Q0J006 →
Q3ZBG0 — 0.991 Q3ZBG0 →
Q5RDH8 — 0.991 Q5RDH8 →
A2YXU2 — 0.991 A2YXU2 →
O94517 — 0.991 O94517 →
P22769 — 0.990 P22769 →
A2Z3I9 — 0.990 A2Z3I9 →
Q9Z2U0 — 0.990 Q9Z2U0 →
P30186 — 0.990 P30186 →
Q9PVQ1 — 0.990 Q9PVQ1 →
PSMA7 Proteasome subunit alpha type-7 0.990 landscape →
PSMA8 Proteasome subunit alpha-type 8 (Proteasome a 0.990 landscape →
O81147 — 0.990 O81147 →
O24616 — 0.989 O24616 →
Q9PTW9 — 0.989 Q9PTW9 →
Q4R7D9 — 0.989 Q4R7D9 →
Q6YT00 — 0.989 Q6YT00 →
P40303 — 0.989 P40303 →
O13268 — 0.988 O13268 →
O16811 — 0.988 O16811 →
Q9XG77 — 0.988 Q9XG77 →